Barclays analyst Andrew Mok raised the firm’s price target on Centene (CNC) to $44 from $35 and keeps an Equal Weight rating on the shares following the Q3 report. The company’s 2025 Medicaid margins are ending the year higher, helped by actions in Florida and New York, but Centene no longer expects 2026 margin improvement, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC: